146 related articles for article (PubMed ID: 22516052)
21. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
22. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
24. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
25. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
26. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
[TBL] [Abstract][Full Text] [Related]
27. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
Pan JH; Han JX; Wu JM; Huang HN; Yu QZ; Sheng LJ
Respiration; 2009; 78(1):49-55. PubMed ID: 18812689
[TBL] [Abstract][Full Text] [Related]
28.
Li YQ; Zhang XY; Chen J; Yin JY; Li XP
J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
[TBL] [Abstract][Full Text] [Related]
29. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.
Xu J; Tian S; Yin Z; Wu S; Liu L; Qian Y; Pei D; Gao W; Xu J; Yin Y; Liu P; Shu Y
Lung Cancer; 2014 Sep; 85(3):442-8. PubMed ID: 24997136
[TBL] [Abstract][Full Text] [Related]
31. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
[TBL] [Abstract][Full Text] [Related]
32. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
[TBL] [Abstract][Full Text] [Related]
33. DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives.
Fikrova P; Stetina R; Hrnciarik M; Hrnciarikova D; Hronek M; Zadak Z
Oncol Rep; 2014 Jan; 31(1):391-6. PubMed ID: 24154806
[TBL] [Abstract][Full Text] [Related]
34. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
36. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
37. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.
Xu X; Han L; Yang H; Duan L; Zhou B; Zhao Y; Qu J; Ma R; Zhou H; Liu Z
Lung Cancer; 2013 Jan; 79(1):65-72. PubMed ID: 23127338
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
[TBL] [Abstract][Full Text] [Related]
39. An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.
Zhu X; Lin MCM; Fan W; Tian L; Wang J; Ng SS; Wang M; Kung H; Li D
Chest; 2012 Jun; 141(6):1466-1472. PubMed ID: 21940774
[TBL] [Abstract][Full Text] [Related]
40. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
Tan XL; Moyer AM; Fridley BL; Schaid DJ; Niu N; Batzler AJ; Jenkins GD; Abo RP; Li L; Cunningham JM; Sun Z; Yang P; Wang L
Clin Cancer Res; 2011 Sep; 17(17):5801-11. PubMed ID: 21775533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
